CS1001, an anti-PD-L1 antibody, combined with Standard of Care (SOC) Chemotherapy for First Line (1L) Advanced GC/GEJ and ESCC: Preliminary Results from 2 Phase 1b Cohorts of CS1001-101 Study

CS1001, an anti-PD-L1 antibody, combined with Standard of Care (SOC) Chemotherapy for First Line (1L) Advanced GC/GEJ and ESCC: Preliminary Results from 2 Phase 1b Cohorts of CS1001-101 Study

A Phase 1b study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with first-line (1L) unresectable hepatocellular carcinoma (uHCC)

A Phase 1b study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC)

Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) solid tumors: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W)

Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumors: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing

GEMSTONE-302: Randomized, Double-Blind, Phase 3 Study of Sugemalimab or Placebo Plus Platinum-Based Chemotherapy as First-Line Treatment for Metastatic NSCLC

Phase 1 Study of Fisogatinib (BLU-554) in Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC) Expressing FGF19: Preliminary Results from Tyrosine Kinase Inhibitor (TKI)-naïve Chinese Pts in Part 3 of the Study